Company / Operating Cash Flow
RECURSION PHARMACEUTICALS, INC. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$371.8M
FY2025
5-year range
-$371.8M / -$45.4M
FY2021-FY2025
Trend
-3.5%
vs FY2024
Sector context
#200 of 216
Health Care
What the data says
Among 216 Health Care companies, RECURSION PHARMACEUTICALS, INC. is in the bottom 7% for operating cash flow. Operating Cash Flow has declined for 3 consecutive years, from -$45M in FY2022 to -$372M in FY2025.
Based on SEC 10-K filings.
-$372M in FY2025.
Declined from -$288M to -$372M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 216This company -$371.8M Sector average $659.0M
▼
-156.4% below sector average
Key checks
Key Insights
- RECURSION PHARMACEUTICALS, INC.'s operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 3.5% year-over-year.
- Ranks #200 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.80 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$371.8M | -3.5% |
| FY2024 | -$359.2M | -24.8% |
| FY2023 | -$287.8M | -533.9% |
| FY2022 | -$45.4M | +71.4% |
| FY2021 | -$158.6M | -249.4% |
| FY2020 | -$45.4M | +20.4% |
| FY2019 | -$57.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026